Suppr超能文献

丙型肝炎病毒非结构蛋白5B的S282和G283与模板链之间复杂的相互作用网络影响对索磷布韦和利巴韦林的敏感性。

A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin.

作者信息

Kulkarni Anupriya S, Damha Masad J, Schinazi Raymond F, Mo Hongmei, Doehle Brian, Sagan Selena M, Götte Matthias

机构信息

Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.

Department of Chemistry, McGill University, Montreal, Quebec, Canada.

出版信息

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2018-27. doi: 10.1128/AAC.02436-15. Print 2016 Apr.

Abstract

The hepatitis C virus (HCV) RNA-dependent RNA-polymerase NS5B is essentially required for viral replication and serves as a prominent drug target. Sofosbuvir is a prodrug of a nucleotide analog that interacts selectively with NS5B and has been approved for HCV treatment in combination with ribavirin. Although the emergence of resistance to sofosbuvir is rarely seen in the clinic, the S282T mutation was shown to decrease susceptibility to this drug. S282T was also shown to confer hypersusceptibility to ribavirin, which is of potential clinical benefit. Here we devised a biochemical approach to elucidate the underlying mechanisms. Recent crystallographic data revealed a hydrogen bond between S282 and the 2'-hydroxyl of the bound nucleotide, while the adjacent G283 forms a hydrogen bond with the 2'-hydroxyl of the residue of the template that base pairs with the nucleotide substrate. We show that DNA-like modifications of the template that disrupt hydrogen bonding with G283 cause enzyme pausing with natural nucleotides. However, the specifically introduced DNA residue of the template reestablishes binding and incorporation of sofosbuvir in the context of S282T. Moreover, the DNA-like modifications of the template prevent the incorporation of ribavirin in the context of the wild-type enzyme, whereas the S282T mutant enables the binding and incorporation of ribavirin under the same conditions. Together, these findings provide strong evidence to show that susceptibility to sofosbuvir and ribavirin depends crucially on a network of interdependent hydrogen bonds that involve the adjacent residues S282 and G283 and their interactions with the incoming nucleotide and complementary template residue, respectively.

摘要

丙型肝炎病毒(HCV)的RNA依赖性RNA聚合酶NS5B是病毒复制所必需的,也是一个重要的药物靶点。索磷布韦是一种核苷酸类似物的前体药物,它能选择性地与NS5B相互作用,已被批准与利巴韦林联合用于HCV治疗。虽然临床上很少出现对索磷布韦的耐药性,但S282T突变已被证明会降低对该药物的敏感性。S282T突变还被证明会使病毒对利巴韦林超敏感,这具有潜在的临床益处。在此,我们设计了一种生化方法来阐明其潜在机制。最近的晶体学数据显示,S282与结合核苷酸的2'-羟基之间存在氢键,而相邻的G283与与核苷酸底物碱基配对的模板残基的2'-羟基形成氢键。我们发现,模板的DNA样修饰若破坏与G283的氢键,会导致天然核苷酸作用下的酶暂停。然而,模板中特意引入的DNA残基在S282T背景下能重新建立索磷布韦的结合与掺入。此外,模板的DNA样修饰在野生型酶背景下会阻止利巴韦林的掺入,而S282T突变体在相同条件下能使利巴韦林结合并掺入。总之,这些发现提供了有力证据,表明对索磷布韦和利巴韦林的敏感性关键取决于一个相互依赖的氢键网络,该网络分别涉及相邻残基S282和G283及其与进入的核苷酸和互补模板残基的相互作用。

相似文献

2
Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Antiviral Res. 2016 Feb;126:43-54. doi: 10.1016/j.antiviral.2015.12.010. Epub 2015 Dec 24.
3
In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.
Antivir Ther. 2017;22(7):587-597. doi: 10.3851/IMP3149. Epub 2017 Mar 1.
7
Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.
J Viral Hepat. 2015 Nov;22(11):871-81. doi: 10.1111/jvh.12405. Epub 2015 Mar 18.
8
HCV RdRp, sofosbuvir and beyond.
Enzymes. 2021;49:63-82. doi: 10.1016/bs.enz.2021.06.003. Epub 2021 Sep 24.

引用本文的文献

2
Akt Phosphorylation of Hepatitis C Virus NS5B Regulates Polymerase Activity and Hepatitis C Virus Infection.
Front Microbiol. 2021 Oct 22;12:754664. doi: 10.3389/fmicb.2021.754664. eCollection 2021.
3
Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.
Chem Rev. 2021 Mar 24;121(6):3238-3270. doi: 10.1021/acs.chemrev.0c00648. Epub 2021 Jan 7.
6
Novel NS5B Resistance-Associated Substitution Emerges Under Failing Sofosbuvir/Ledipasvir Therapy.
Clin Liver Dis (Hoboken). 2019 Mar 29;13(3):74-78. doi: 10.1002/cld.768. eCollection 2019 Mar.

本文引用的文献

1
Genotype- and Subtype-Independent Full-Genome Sequencing Assay for Hepatitis C Virus.
J Clin Microbiol. 2015 Jul;53(7):2049-59. doi: 10.1128/JCM.02624-14. Epub 2015 Apr 15.
2
Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase.
Science. 2015 Feb 13;347(6223):771-5. doi: 10.1126/science.1259210.
4
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Gastroenterology. 2015 Jan;148(1):100-107.e1. doi: 10.1053/j.gastro.2014.09.023. Epub 2014 Sep 28.
5
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
N Engl J Med. 2014 May 22;370(21):1993-2001. doi: 10.1056/NEJMoa1316145. Epub 2014 May 4.
6
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.
Antimicrob Agents Chemother. 2014;58(4):1930-42. doi: 10.1128/AAC.02351-13. Epub 2014 Jan 13.
8
Nucleotide prodrugs for the treatment of HCV infection.
Adv Pharmacol. 2013;67:39-73. doi: 10.1016/B978-0-12-405880-4.00002-0.
9
Sofosbuvir and ABT-450: terminator of hepatitis C virus?
World J Gastroenterol. 2013 Jun 7;19(21):3199-206. doi: 10.3748/wjg.v19.i21.3199.
10
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.
Ann Intern Med. 2013 Jul 16;159(2):86-96. doi: 10.7326/0003-4819-159-2-201307160-00654.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验